FindTrial
Sign In

Effect of combination of cangrelor and ticagrelor compared to ticagrelor alone in heart attack patients undergoing angioplasty.

Effectiveness and safety of cangrelor in combination with ticagrelor compared to ticagrelor alone in acute coronary syndrome patients undergoing percutaneous coronary intervention- a prospective observational study. - NIl

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/08/092383
Enrollment
60
Registered
2025-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I249- Acute ischemic heart disease, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Cangrelor and ticagrelor: -Cangrelor is given intravenously as a standard bolus dose of 30 g/kg followed by a continuous infusion of 4 g

Sponsors

Mahima Pradhan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients receiving ticagrelor or cangrelor during PCI will be included in the study Patients diagnosed with Acute Coronary Syndrome spectrum ST segment elevation myocardial infarction (STEMI) Non-ST segment elevation myocardial infarction (NSTEMI) Unstable Angina Patients undergoing PCI and eligible for intravenous antiplatelet therapy Patients on with or without aspirin for prophylactic therapy

Exclusion criteria

Exclusion criteria: Patients with a history of major bleeding within the past 6 months Patients who are currently on clopidogrel Patients having active bleeding or bleeding diathesis Patients with history of peptic ulcer and gastrointestinal bleeding Patients with hepatic or renal impairment Patients having hypersensitivity to cangrelor or ticagrelor Pregnant and lactating women Participation in another clinical trial in the past 30 days

Design outcomes

Primary

MeasureTime frame
Compare the effectiveness of intravenous cangrelor with oral ticagrelor in reducing cardiovascular death, myocardial ischemia, stent thrombosis, ischemia driven revascularization, intra-procedural ST segment elevation, major bleeding, stroke and minor bleeding in acute coronary syndrome patients undergoing percutaneous coronary intervention.Timepoint: 24 hours—

Secondary

MeasureTime frame
Assess the safety profile of cangrelor by monitoring bleeding complications.Timepoint: upto 48 hours;Assess the major adverse cardiovascular events (MACE) such as stent thrombosis, myocardial infarction and death after PCITimepoint: 30 days—

Countries

India

Contacts

Public ContactBhuvana K

Sri Devaraj Urs Medical College

drbhuvanak2010@gmail.com9900383738

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026